Drug Delivery for Cancer Immunotherapy and Vaccines

Title:Drug Delivery for Cancer Immunotherapy and Vaccines

Volume: 6 Issue: 4

Author(s): Cole J. Batty, Pamela Tiet, Eric M. Bachelder and Kristy M. Ainslie*

Affiliation:

• Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, The University of North Carolina at Chapel Hill, Chapel Hill, NC,United States

Keywords: Adjuvant, antigen, cytokine, dendritic cells, lymph nodes, microparticle, nanoparticle.

Abstract: Cancer cells are able to avoid immune surveillance and exploit the immune system to grow and metastasize. With the development of nano- and micro-particles, there has been a growing number of immunotherapy delivery systems developed to elicit innate and adaptive immune responses to eradicate cancer cells. This can be accomplished by training resident immune cells to recognize and eliminate cells with tumor-associated antigens or by providing external stimuli to enhance tumor cell apoptosis in the immunosuppressive tumor microenvironment (TME). In this review we will focus on nano- and micro-particle (NP and MP) based immunotherapies and vaccines used to elicit a potent and sustained antitumor immune response.

Cite this article as:

Batty J. Cole, Tiet Pamela , Bachelder M. Eric and Ainslie M. Kristy *, Drug Delivery for Cancer Immunotherapy and Vaccines, Pharmaceutical Nanotechnology 2018; 6 (4) . https://dx.doi.org/10.2174/2211738506666180918122337